Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 7/20 | 0.46 |
| ▸ | HTR2A | P28223 | 3/20 | 0.40 |
| ▸ | HTR2C | P28335 | 3/20 | 0.40 |
| ▸ | HTR2B | P41595 | 3/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | PTPRC | P08575 | 1/20 | 0.37 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | SLC6A1 | P30531 | 1/20 | 0.35 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.35 |
| ▸ | GABRP | O00591 | 1/20 | 0.35 |
| ▸ | GABRD | O14764 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.35 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL20703506 | 0.98 | PNMT (0.45) | PNMTHTR2AHTR2CHTR2BADRA2A | |
| Lithium SCHEMBL30831167 | 0.98 | PNMT (0.45) | PNMTHTR2AHTR2CHTR2BADRA2A | |
| Hydrochloric Acid SCHEMBL30864391 | 0.98 | PNMT (0.45) | PNMTHTR2AHTR2CHTR2BADRA2A | |
| SCHEMBL21413286 | 0.88 | PNMT (0.46) | PNMTHTR2AHTR2CHTR2BADRA2A | |
| SCHEMBL28978402 | 0.86 | PNMT (0.45) | PNMTHTR2AHTR2CHTR2BADRA2A | |
| SCHEMBL15445349 | 0.86 | PNMT (0.45) | PNMTHTR2AHTR2CHTR2BADRA2A | |
| SCHEMBL27044246 | 0.85 | PNMT (0.39) | PNMTHTR2AHTR2CHTR2BADRA2A | |
| SCHEMBL10129638 | 0.82 | PNMT (0.42) | PNMTHTR2AHTR2CHTR2BADRA2A | |
| Hydrochloric Acid SCHEMBL23422078 | 0.81 | PNMT (0.41) | PNMTHTR2AHTR2CHTR2BADRA2A | |
| SCHEMBL13894060 | 0.81 | EGLN1 (0.42) | PNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118546127-B | Litasai Special synthetic method | 成都天兴致远生物科技有限公司 | 2024-09-20 | — | — | CN | claimed |
| CN-118546127-A | Litasai Special synthetic method | 成都天兴致远生物科技有限公司 | 2024-08-27 | — | — | CN | claimed |
| CN-115557939-A | Method for preparing high-purity sitaxetil | 广东和博制药有限公司 | 2023-01-03 | — | — | CN | claimed |
| WO-2019043724-A1 | PROCESSES FOR THE PREPARATION OF (S)-2-(2-(BENZOFURAN-6-CARBONYL)-5,7-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE-6-CARBOXAMIDO)-3-(3-(METHYLSULFONYL)PHENYL) PROPANOIC ACID AND POLYMORPHS THEREOF | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2019-03-07 | — | — | WO | claimed |
| CN-118684605-A | Preparation of ritgasan Process for the preparation of intermediates | 山东新时代药业有限公司 | 2024-09-24 | — | — | CN | disclosed |
| CN-118546127-B | Litasai Special synthetic method | 成都天兴致远生物科技有限公司 | 2024-09-20 | — | — | CN | disclosed |
| CN-118546127-B | Litasai Special synthetic method | 成都天兴致远生物科技有限公司 | 2024-09-20 | — | — | CN | disclosed |
| CN-118546127-A | Litasai Special synthetic method | 成都天兴致远生物科技有限公司 | 2024-08-27 | — | — | CN | disclosed |
| CN-118546127-A | Litasai Special synthetic method | 成都天兴致远生物科技有限公司 | 2024-08-27 | — | — | CN | disclosed |
| CN-118420572-A | Synthesis method of medicine intermediate benzofuran-6-carboxylic acid | 山东新时代药业有限公司 | 2024-08-02 | — | — | CN | disclosed |
| CN-118420573-A | Preparation method of litaxetil intermediate benzofuran-6-carboxylic acid | 山东新时代药业有限公司 | 2024-08-02 | — | — | CN | disclosed |
| CN-118420531-A | Preparation method of ritalst intermediate | 山东新时代药业有限公司 | 2024-08-02 | — | — | CN | disclosed |
| US-20130150585-A1 | Crystalline Pharmaceutical and Methods of Preparation and Use Thereof | SARcode Bioscience, Inc. (US) | 2013-06-13 | — | — | US | disclosed |
| US-20130144063-A1 | Crystalline Pharmaceutical and Methods of Preparation and Use Thereof | SARCODE BIOSCIENCE INC. (US) | 2013-06-06 | — | — | US | disclosed |
| US-8378105-B2 | Crystalline pharmaceutical and methods of preparation and use thereof | SARCODE BIOSCIENCE INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-8367701-B2 | Crystalline pharmaceutical and methods of preparation and use thereof | SARCODE BIOSCIENCE INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20120107404-A1 | Crystalline Pharmaceutical and Methods of Preparation and Use Thereof | SARCODE BIOSCIENCE INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-8080562-B2 | Crystalline pharmaceutical and methods of preparation and use thereof | SARCODE BIOSCIENCE INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-20110092707-A1 | Crystalline Pharmaceutical and Methods of Preparation and Use Thereof | SARCODE CORPORATION (US) | 2011-04-21 | — | — | US | disclosed |
| US-20090298869-A1 | Crystalline pharmaceutical and methods of preparation and use thereof | CITIBANK, N.A., AS NOTES COLLATERAL AGENT | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120107404-A1 | Crystalline Pharmaceutical and Methods of Preparation and Use Thereof | VCAM1, ICAM1, HLA-DRB1 | PNMT 3959/4885HTR2A 2926/4885HTR2C 3430/4885 |
| US-20130144063-A1 | Crystalline Pharmaceutical and Methods of Preparation and Use Thereof | VCAM1, ICAM1, HLA-DRB1 | PNMT 3959/4885HTR2A 2926/4885HTR2C 3430/4885 |
| US-20090298869-A1 | Crystalline pharmaceutical and methods of preparation and use thereof | VCAM1, ICAM1, HLA-DRB1 | PNMT 3959/4885HTR2A 2926/4885HTR2C 3430/4885 |
| US-20110092707-A1 | Crystalline Pharmaceutical and Methods of Preparation and Use Thereof | VCAM1, ICAM1, HLA-DRB1 | PNMT 3959/4885HTR2A 2926/4885HTR2C 3430/4885 |
| US-20130150585-A1 | Crystalline Pharmaceutical and Methods of Preparation and Use Thereof | VCAM1, ICAM1, HLA-DRB1 | PNMT 3959/4885HTR2A 2926/4885HTR2C 3430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.